SUBSCRIBERS
Samsung's drug-making unit soars on market debut
Published Thu, Nov 10, 2016 · 09:50 PM
Seoul
SHARES in Samsung's drug-making unit soared almost six per cent on their market debut on Thursday, after one of South Korea's biggest ever initial public offerings that raised nearly US$2 billion.
Samsung Biologics, a contract manufacturer of biotech drugs for global pharmaceutical firms, surged 5.88 per cent from its IPO price to close at 144,000 won (S$174) in Seoul, putting its total value at about 9.5 trillion won.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Sheng Siong Q1 net profit up 9.3% on higher revenue
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Cordlife customers push for legal action